Skip to main content

Table 3 Baseline characteristics of HCV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008

From: The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

  Total N=1175 HCV chronically infected patients N=1048 Sustained HCV responders N=127
Years since HCV diagnosis, median (IQR) - 10 (6-14) -
HCV genotype, N (%) -   -
   1   577 (56.0)  
   2   39 (3.8)  
   3   187 (18.1)  
   4   225 (21.8)  
   5 or other   3 (0.3)  
HCV plasma RNA (Log10) (IU/ML), median (IQR) - 6.2 (5.7-6.5) -
Past anti HCV therapy, N (%)    
   Interferon alone 40 (3.4) 33 (3.1) 7 (5.5)
   Interferon+ ribavirin 93 (7.9) 65 (6.2) 28 (22)
   Pegylated interferon plus ribavirin 365 (31.1) 273 (26.0) 92 (72.5)
Cirrhosis*, N (%) 255 (25.2) 229 (25.0) 26 (26.8)
Documented decompensated liver disease, N (%) 32 (2.7) 27 (2.6) 5 (3.9)
  1. * according to the study algorithm of cirrhosis (see Figure 1 )
\